Overcoming the efficacy-safety dilemma of cytokine therapy for tissue-resident memory T cells in cancer immunotherapy: Intrinsic sensitization and extrinsic optimization.
Abstract
Tissue-resident memory T (TRM) cells are important contributors to immune checkpoint blockade therapy response in several cancers, yet their therapeutic potential remains underutilized. The cytokine-mediated enhancement of TRM cells represents a promising strategy to amplify antitumor immunity. However, clinical translation is hindered by an efficacy-safety dilemma. Potent cytokines such as IL-12 and IL-15 induce severe systemic toxicity; other potent cytokines such as TGF-β and IL-1 carry inherent immunosuppressive risks. To overcome this barrier, a dual-strategy framework is proposed. Intrinsic sensitization involves the use of multidimensional regulatory networks such as those involving transcription factors, metabolic pathways, hypoxia signaling, and host aging to enhance TRM responsiveness to cytokines rather than increasing the dose. Complementing this, extrinsic optimization minimizes risks through targeted delivery systems, tumor microenvironment (TME) modulation for endogenous release, rational cytokine combination, and protein engineering coupled with rational selection. Collectively, this roadmap outlines how to harness cytokine networks safely and effectively, enabling precision TRM-based antitumor immunotherapy.